The Efficacy of Omega-3 Supplement on Prevention of Retinopathy of Prematurity in Premature Infants: A Randomized Double-blinded Controlled trial.
Curr Pharm Des
; 24(17): 1845-1848, 2018.
Article
em En
| MEDLINE
| ID: mdl-29852863
ABSTRACT
BACKGROUND:
The present study aimed to assess the efficacy of omega-3 in treating ROP in premature infants.METHODS:
This randomized double-blinded controlled trial was performed on 160 premature infants with gestational age lower than 32 weeks and birth weight < 1500 grams who were at risk of ROP development (Tehran, Iran-2013). Children were randomly assigned to two groups. The intervention group received 300 mg omega-3 daily and the control group received sterile water as the placebo. The severity of ROP was defined according to the International Classification of ROP.RESULTS:
The frequency of ROP was 7.5% in the group received omega-3 and 20.0% in the placebo group with a significant difference (p = 0.021). Regarding the severity of ROP in the intervention group, ROP grade I was found in two patients and ROP grade II in four patients; while ROP grade I, II, and III were revealed in 6, 6, and 4 patients in placebo group indicating a significant difference between the two groups (p = 0.001). Using the multivariate logistic regression modeling with the presence of gender, gestational age, and birth weight, the use of omega-3 was associated with reduced risk for ROP (p = 0.045).CONCLUSION:
The use of omega-3 supplement can be an appropriate treatment option for the treatment of ROP in premature infants.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Retinopatia da Prematuridade
/
Ácidos Graxos Ômega-3
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Infant
/
Male
/
Newborn
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article